Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Eli LillyFinanical Reports

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly and Company (NYSE: LLY) reported third‑quarter 2026 worldwide revenue of USD 24.4 billion, up 39% year‑on‑year, driven by strong demand for its diabetes and obesity treatments Mounjaro (tirzepatide)…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent
CVDProduct approvals

Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent

NMPA Approves World's First Plant-Based Human Albumin for Liver Cirrhosis Treatment
Product approvals

NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment

KANTE Biotech's Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection
CancerKANTE Biotechnology

KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection

WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings
CRO / CMO / CDMOHKG: 2269

WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings

Show More